SEOUL, June 2 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, has established a one-stop production capability for manufacturing messenger RNA (mRNA) vaccines by newly adding a mRNA vaccine substance production facility at its plant, a company official said Thursday. According to the official, Samsung has completed the addition [...]
SEOUL, May 24 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, is shutting down its joint venture with multinational pharmaceutical company AstraZeneca Plc., a company official said Tuesday, due to the suspension of the development of a biosimilar product. The move came two months after Samsung Biologics’ board approved [...]
SEOUL, April 20 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Wednesday it has completed the first payment to acquire the U.S. drugmaker’s entire stake in Samsung Bioepis. Earlier, Samsung Biologics reached a deal with Biogen to purchase the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 [...]
SEOUL, March 29 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, aims to expand its presence in the global market through full ownership of Samsung Bioepis, its chief executive said Tuesday. Samsung Biologics is the leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of [...]
SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday that it has reached a deal with Biogen Inc. to buy the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 billion. Currently, Biogen owns 50 percent minus one share in Samsung Bioepis, the joint venture [...]
SEOUL, Jan. 13 (Korea Bizwire) — Samsung Biologics, a major South Korean contract drug manufacturer, said Thursday it plans to start building a fifth plant this year to meet rising orders. The company’s fourth plant, currently under construction, is set to be partially operational from October starting with a bioreactor capacity of 60,000 liters, CEO [...]
SEOUL, Dec. 14 (Korea Bizwire) — British-Swedish pharmaceutical giant AstraZeneca said Tuesday that Samsung Biologics Co., the biotech arm of Samsung Group, will manufacture its antibody combination against COVID-19. Under an agreement valued at approximately US$380 million, Samsung Biologics will manufacture AZD7442 — AstraZeneca’s combination of two long-acting antibodies in development for the potential treatment [...]
SEOUL, Nov. 25 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. said Thursday it has signed a supply agreement with U.S.-based biotech company GreenLight Biosciences. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will manufacture drug substances for GreenLight’s mRNA COVID-19 vaccine candidate. Samsung Biologics will manufacture drug substances of the mRNA [...]
SEOUL, Oct. 28 (Korea Bizwire) – Samsung Biologics Co., a major South Korean contract drugs manufacturer, on Thursday began to supply the first batch of Moderna vaccines manufactured in South Korea. In May, the biotech unit of South Korea’s largest conglomerate Samsung Group, signed a contract with Moderna Inc. to provide contract manufacturing organization services [...]
SEOUL, Oct. 26 (Korea Bizwire) — The first batch of 2.43 million doses of Moderna vaccines manufactured by South Korean biopharmaceutical firm Samsung Biologics Co. will be provided here this week, health authorities said Tuesday. In May, the biotech unit of Samsung Group signed a contract with the U.S. drugmaker to provide contract manufacturing organization [...]